They'll wait for the capital raise until FDA approval for Phase III trial in Quarter 1 CY2024, IMO.
Cash burn will decrease now that the Phase II is pretty much finished, so I expect 4th quarter 2023 to be a relatively low burn quarter cf recent quarters.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.020(4.55%) |
Mkt cap ! $166.9M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 44.5¢ | 41.5¢ | $271.6K | 637.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5960 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 3696 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |